Globally, injectable medications form the second most preferred class of drugs, with oral route of administration leading the global pharma market. Injectable drug delivery devices have evolved from traditional needles and syringes to recently developed needle-free injectors. The market has evidenced a shifting trend from administration of injections in clinician settings to home care settings, which has resulted in increasing the focus of industry players towards the development of user friendly and patient compliant devices.
On the drug delivery formulation front, novel drug delivery technologies and applications of nanotechnology have resulted in the development of targeted drug delivery carriers such as liposomes, microspheres and polymeric micelles. PEGylation of these nanoparticles enables sustained release of drugs at the target site. Rising need of targeted and sustained drug delivery in the treatment of chronic diseases and need of cost efficient delivery of high priced medications is expected to drive this market.
Growth of biologics and entry of biosimilars in leading pharma markets such as the U.S. and Europe is expected to be the key driver for growth of the injectable drug delivery market for the forecast period (2010-2015).
Driven by above mentioned factors, the global injectable drug delivery market is expected to reach a level of $29,981 million in 2015 from $14,994 million in 2009 at a CAGR of 12.3% during 2010-2015.
Markets Covered
The report evaluates injectable drug delivery market with respect to revenues, growth, therapeutic areas and industry focus in the following markets:
Injectable drug delivery devices technology market
Injectable drug delivery formulation technology market
Injectable drug delivery therapeutics market
The report provides market estimates and forecasts for the global injectable drug delivery market in North America, Europe, Asia, and Rest of the World (ROW). In addition to market sizing and forecasts, the report also offers a detailed analysis of the market trends, opportunities, and factors influencing the growth of each segment of the injectable drug delivery market.
Stakeholders
The targeted audience for this report includes:
Manufacturers, suppliers and dealers of injectable drug delivery technologies
Pharmaceutical and biotech companies
Potential investors in the drug delivery technology market
1. Market Overview
1.1. Evolution and value chain analysis of Injectable Market
1.2. Injectable market Vs markets for other modes of drug delivery
1.2.1. Market transitions (Short, medium and long term perspective)
1.2.2. Reason for extending scope for injectables
1.2.3. Technological innovations for injectables vs. alternative drug delivery system (micro-electromechanical devices, PEGylation, Nano-enabled injectables)
1.3. Injector design criteria
1.4. Novel drug/compound/Drug discovery technologies (proteomics, genomics etc) introduction demanding innovations in mode of drug delivery and future impacts
1.5. Legislations and Regulatory issues – Level of impacts of market
1.6. Key market dynamics and opportunities
1.7. Patent analysis
1.7.1. By Market participant
1.7.2. By geography
1.8. Strategic recommendations
2. Market Summary - Total Injectable Drug Delivery Market
(Key market trends and total market forecast)
2.1. Key Market Drivers
2.2. Key Restraints
2.3. Key Opportunities
3. Market Segmentation for Injectable Drug Delivery Market
(Key drivers, restraints, opportunities, strategic analysis, market forecast for each of the markets)
3.1. Injectable Drug Delivery Systems
3.1.1. Sustained Release Injectable Systems
3.1.2. Needleless Systems
3.1.3. Microneedle Injectors
3.1.4. Liposomal Systems/ PEGylation
3.1.5. Novel Injectable Technologies
3.2. Injectable – By Mode of Drug Delivery
3.2.1. Intradermal
3.2.2. Subcutaneous
3.2.3. Intramuscular
3.2.4. Intravenous
3.2.5. Intraosseous
3.2.6. Intraperitoneal
3.3. By Therapeutics
3.3.1. Acromegaly
3.3.2. Age-Related Macular Degeneration
3.3.3. Crohn’s Disease
3.3.4. Diabetes
3.3.5. Hepatitis C
3.3.6. Multiple Sclerosis
3.3.7. Neutropenia
3.3.8. Oncology
3.3.9. Pain
3.3.10. Psoriasis
3.3.11. Rheumatoid Arthritis
3.3.12. Other (Emergency)
3.4. Markets by Reusability
3.4.1. Reusable
3.4.2. Disposable
3.4.2.1. Conventional
3.4.2.2. Next-Generation Disposable Injection (Auto disable injectors and Auto injectors)
3.4.3. Pre-filled
3.4.4. Custom
3.5. Drug Classes Delivered (Sample)
3.5.1. Antimuscarinics
3.5.2. Cytokines
3.5.3. Dopamine
3.5.4. Hematopoietics
3.5.5. Human Growth Hormone
3.5.6. Insulins and Antihyperglycemics
3.5.7. Interferons
3.5.8. Parathyroid Hormone
3.5.9. Reproductive Hormones
3.5.10. Serotonin Antagonists
3.5.11. Sympathomimetics
3.5.12. Others
4. Competitive Landscape
4.1. Key market players (Market segment specific)
4.2. Market position and market share (Depending on the nature of market)
4.3. Market Strategies (Top tier companies strategy Vs regional player’s strategy)
4.4. List of M&A and New Product Launch
4.5. Other recent strategic developments among the industry participants
5. Sample Company Profiles
5.1. Alkermes
5.2. ALZA
5.3. Aradigm
5.4. Bioject
5.5. Enzon
5.6. Ethypharm
5.7. MacroMed
5.8. Nektar Therapeutics
5.9. QLT
5.10. SkyePharm
5.11. Others
6. Appendix
6.1. List of patents
6.1.1. U.S.
6.1.2. Europe
6.1.3. Japan.
Other selected research from the 'Drug Delivery' category:
Drug Delivery Markets: Oral Delivery
Top 10 Drug Delivery Technologies (2010 - 2015)
Other selected research from the 'Drugs' category:
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2012
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2012